The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma
NCT ID: NCT01266434
Last Updated: 2016-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
44 participants
INTERVENTIONAL
2011-01-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma
NCT00792337
Control of Asthma Patients Symptomatic on Inhaled Corticosteroids
NCT00330070
Effectiveness of Anti-IL-5/IL5R Inhibitors
NCT06239441
Inflammatory Markers in Exhaled Breath Condensates From Asthmatic Patients
NCT01246414
A 12-Week Study in Adult Subjects With Asthma
NCT01516086
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
simvastatin
Simvastatin
10 mg once daily for 8 weeks
B1-6-12
Simvastatin
10 mg once daily for 8 weeks
B1-6-12
1 tablet once daily for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Simvastatin
10 mg once daily for 8 weeks
B1-6-12
1 tablet once daily for 8 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* FEV1 = OR \> 50% of predicted
Exclusion Criteria
* Previous history of liver disease.
* Pregnancy or lactation.
* Are already receiving or are known to be allergic to statins or to have developed myositis.
* Have an asthma exacerbation requiring treatment with oral corticosteroids during the 3 months prior to the commencement of study entry.
* Being treated with immunosuppressive agents.
* Unwilling to cooperate the study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mahidol University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kittipong Maneechotesuwan
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kittipong - Maneechotesuwan, MD., PhD.
Role: PRINCIPAL_INVESTIGATOR
Siriraj Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Respiratory Disease and TB, Siriraj Hospital
Bangkoknoi, BKK, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
si481/2010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.